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The role of microRNA-30a (miR-30a) deregulation in tumor progression and its downstream signal-
ing pathways remain unknown. Here we conﬁrmed signiﬁcant downregulation of miR-30a in hepa-
tocellular carcinoma (HCC) tissues and cell lines compared with non-tumor counterparts. MiR-30a
downregulation was signiﬁcantly associated with worse disease-free survival (DFS) of HCC patients.
Gain- and loss-of-function studies revealed that downregulation of miR-30a facilitated tumor cell
migration, invasion and epithelial–mesenchymal transition (EMT). We identiﬁed SNAI1 as a direct
target of miR-30a and demonstrated miR-30a as a novel regulator of EMT by targeting SNAI1, indi-
cating its potential therapeutic value for reducing invasion and metastasis of HCC.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is currently one of the most
common malignancies and the leading cause of cancer death
worldwide [1–3]. Multiple studies have conﬁrmed the aberrant
expression of small noncoding microRNAs (miRNAs) in HCC [4–
8]. These ﬁndings suggest that downregulated miRNAs may be
associated with tumorigenesis and progression in HCC. Recent
reports demonstrated that the expression of miR-30 family mem-
bers (miR-30a/b/c/d/e) was signiﬁcantly reduced in several human
cancers, and this reduction also indicated a poor prognosis [9–11].
We previously reported that miR-30 family members, especially
miR-30a, were signiﬁcantly downregulated in HCC tissues. How-
ever, the role of miR-30a deregulation in HCC and the molecular
mechanisms by which miR-30a exerts its function are still
unknown.
Invasion and metastasis are major causes of death in patients
suffering from HCC. The process of transition from an epithelial
to a mesenchymal state, known as the epithelial–mesenchymal
transition (EMT), is a major characteristic of metastasizing cells[12]. During EMT, the loss of epithelial functions and the acquisi-
tion of mesenchymal functions result in increased cell migration
and invasion. E-cadherin and vimentin function as representative
epithelial-speciﬁc and mesenchymal-speciﬁc protein markers,
respectively. Reduced E-cadherin protein expression and increased
expression of vimentin protein are used as markers indicating an
epithelial cell has undergone EMT [13]. Recent studies suggest that
EMT associated with poor prognosis in cancer patients is a key step
in the invasion and metastasis of tumor cells [10,14,15].
SNAI1, one of the EMT-associated transcription factors, inhibits
E-cadherin expression and promotes tumor cell migration and
invasion [16]. Aberrant expression of SNAI1 during EMT was
detected in several cancer cell lines. In addition, SNAI1-induced
E-cadherin downregulation has been demonstrated essential for
triggering EMT [17]. In recent years, increasing evidence has
shown that SNAI1 plays an essential role in regulating EMT.
In this study, we showed that miR-30a expression was reduced
in the majority of examined HCC tissues, and its downregulation
was signiﬁcantly associated with worse DFS of HCC patients. Fur-
thermore, both gain- and loss-of-function studies revealed that
downregulation of miR-30a could facilitate tumor migration and
invasion by regulating EMT. Moreover, we found that the SNAI1
transcription factor was a direct target of miR-30a, and it was
involved in the effect of reduced miR-30a in enhancing cell
migration, invasion and EMT changes. Our ﬁndings will help to elu-
cidate the functions of miR-30a and its roles in malignant tumor
progression.
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2.1. Tissue specimens
Human HCC tissues and para-cancerous tissues were collected
from 63 patients undergoing resection of HCC at the Center of
Hepatobiliary Surgery of the First Afﬁliated Hospital of Xi’an Jiao-
tong University, P.R. China. The patient characteristics are shown
in Supplementary Table 1. Informed consent was obtained from
each patient and the study was approved by the Xi’an Jiaotong Uni-
versity Ethics Committee. Detailed information is provided in the
Supplementary Materials and Methods.
2.2. Cell lines
MHCC97H, Hep3B, SMMC7721, HepG2, Huh7 (all HCC cells),
LO2 (normal human liver cells), and HEK293T (transformed human
embryonic kidney cells) were obtained from Fudan University of
China and maintained in our lab. All cell lines were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM; Invitrogen, NY) supple-
mented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT).Fig. 1. Expression analysis of miR-30a in HCC tissues and cell lines. (A) MiR-30a was mea
tissues. Relative expression was determined (delta-delta Ct) compared with the internal
expression in the corresponding para-cancerous tissues. MiR-30a expression was downre
in HCC cells compared with LO2 normal human liver cells. Total RNA from LO2, HepG
expression by qPCR. Relative expression was determined (delta-delta Ct) compared with
of miR-30a in HCC tissues with metastasis (n = 18) were signiﬁcantly lower than in tho2.3. Transfection of miRNA mimics and inhibitors
Cells were seeded at 1  105 cells per well in a six-well plate
and transfected with synthetic miRNA mimics or inhibitors
(Biomics, Nantong, China) at a ﬁnal concentration of 50 nM using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Total RNA and protein were collected
3 days post-transfection for experimental analyses. The sequences
of miR-30a were as follows: sense 50-GAAGGUCAGCUCCUACAAAU-
GU-30 and antisense 50-AACAUUUGUAGGG CUGACCUUC-30; the
sequence of the miR-30a inhibitor was as follows: 50-AACAUUU-
GUAGGAGCUGACCUUC-30. The sequences of miR-NC were as
follows: sense 50-UUCUCCGAACGUGUCACGUdTdT-30 and antisense
50-ACGUGACACGUUCGGAGAAdTdT-30; the sequence of the anti-
miR-NC was as follows: 50-GUGGAUAUUGUUGCCAUCA-30.
2.4. Wound healing assay
HCC cells were seeded onto 6-well plates and cultured to con-
ﬂuency. Scratch wounds were made with a 1000-ll pipette tip.
The wounds were photographed with a phase-contrast microscopesured by qPCR in total RNA isolated from 63 pairs of HCC tissues and para-cancerous
control RNU6B, and results are presented as fold change (log2) compared with the
gulated in 87% (55/63) of the HCC cases examined. (B) MiR-30a was downregulated
2, Huh7, Hep3B, SMMC7721 and MHCC97H cell lines were analyzed for miR-30a
the internal control RNU6B. Data are presented as mean ± SEM (n = 3). (C) The levels
se without metastasis (n = 45). ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
Fig. 2. Kaplan–Meier DFS analysis for HCC patients according to miR-30a level. The
miR-30a level was analyzed by qPCR and the median value of all 63 cases was
chosen as the cut-off point for separating miR-30a low-expression tumors (n = 32)
from miR-30a high-expression cases (n = 31). P = 0.015.
Table 1
Univariate and multivariate analysis of factors associated with disease free survival.a
Clinical variables Case
number
HR
(95% CI)
P valuec
Univariate analysis
MiR-30a (low versus high)b 32/31 2.3(1.1–4.6) 0.019
Age (P50 versus <50 years) 27/36 1.0(0.5–2.0) 0.910
Sex (M versus F) 53/10 1.6(0.6–4.7) 0.353
HBV (positive versus negative) 54/9 1.0(0.4–2.7) 0.904
Cirrhosis (yes versus no) 57/6 1.2(0.4–3.8) 0.810
Ascites (yes versus no) 12/51 1.3(0.6–2.9) 0.481
Portal vein tumor thrombus
(yes versus no)
8/55 3.3(1.3–8.4) 0.012
AFP (P400 versus <400 ng/mL) 34/29 1.2(0.6–2.3) 0.639
ALT (P50 versus <50 U/L) 37/26 1.0(0.5–1.9) 0.891
Intrahepatic metastasis (yes versus no) 44/19 1.6(0.8–3.5) 0.209
Hepatic capsule invasion (yes versus no) 9/54 0.9(0.3–2.5) 0.792
Tumor size (P5 cm versus <5 cm) 41/22 2.6(1.2–5.7) 0.020
Tumor number (>1 versus 1) 13/50 0.7(0.3–1.7) 0.458
TNM stage (II/III versus I) 33/30 2.4(1.2–4.9) 0.014
Edmondson grade (>II versus I-II) 37/26 2.3(1.1–4.7) 0.006
Multivariate analysis
MiR-30a (low versus high)b 32/31 3.2(1.5–6.8) 0.002
Portal vein tumor thrombus
(yes versus no)
8/55 2.4(0.9–6.4) 0.082
Tumor size (P5 cm versus <5 cm) 41/22 2.9(1.3–6.7) 0.013
TNM stage (II/III versus I) 33/30 2.0(1.0–4.3) 0.060
Edmondson grade (>II versus I-II) 37/26 2.8(1.3–6.1) 0.008
a Analysis was performed on 63 cases. Hazard ratios (95% conﬁdence interval)
and P values were calculated using Univariate or multivariate Cox proportional
hazards regression.
b The miR-30a level was examined by real-time qPCR and normalized to U6 level.
The median value of all 63 samples was chosen as the cut-off point for separating
miR-30a low tumors from miR-30a high cases.
c Boldface P values indicate statistical signiﬁcant.
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width of the wounds. Migration was calculated as (%) = [⁄W
(0 h) ⁄W (24 h or 48 h)]/W (0 h), in which ⁄W (0 h, 24 h or 48 h)
indicates the width of the wound at 0 h, 24 h or 48 h, respectively.
The experiments were performed with at least ﬁve replicates.
2.5. Transwell invasive assay
The invasion assay was performed using 24-well Transwell
units (BD Biosciences) with 8 lm porosity polycarbonate ﬁlters.All the ﬁlters were coated with 50 lg reconstituted basement
membrane matrix (Matrigel; BD Biosciences). Details are in the
Supplementary Materials and Methods.
2.6. RNA extraction and real-time quantitative polymerase chain
reaction (qPCR)
Total RNA from cultured cells was extracted using Trizol (Life
Technologies, CA, USA), and total RNA was extracted from HCC
tissues using a High Pure miRNA Isolation Kit (TaKaRa Biotechnol-
ogy, Dalian, China) according to the manufacturer’s instructions.
qPCR was performed as described in the Supplementary Materials
and Methods.
2.7. Immunohistochemical analysis
Parafﬁn-embedded, formalin-ﬁxed tissues were immunostained
for E-cadherin, vimentin and SNAI1 as described in the Supplemen-
tary Materials and Methods. Staining was evaluated under a light
microscope at a magniﬁcation of 400. For each specimen, ﬁve
images were quantiﬁed using image optical density (IOD) by
Image-Pro plus software (version 6.0). Measurements of each sample
are the mean IOD of all the ﬁve images (mean IOD = IOD SUM/5).
2.8. Luciferase reporter assay
The luciferase assay was performed in HEK293T and MHCC97H
cells as described in the Supplementary Materials and Methods.
2.9. Western blot analysis
Cells were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl,
1% TritonX-100, 5 mM ethylenediaminetetraacetic acid). Protein con-
centration was determined using the BCA Kit (Pierce, IL, USA). Protein
samples (30 lg) were separated by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis and transferred to a nitrocellulose mem-
brane. The blots were then probed with antibodies against
E-cadherin (1:1000; Cell Signaling Technology, MA, USA), vimentin
(1:1000; Cell Signaling Technology), SNAI1 (1:1000; Cell Signaling
Technology) and b-actin (1:1500, Boster, Wuhan, China). Blots were
then incubated with the appropriate ﬂuorescent secondary antibody
(1:7000; Boster). Images were acquired by the Bio-Rad Gel imaging
system and analyzed by the software program as speciﬁed by Bio-Rad.
2.10. Rescue experiment
Functional rescue experiments were performed by cotransfec-
tion of miR-30a or anti-miR-30a with plasmid constructs express-
ing SNAI1. EMT-related protein markers and migration and
invasion of MHCC97H cells were then measured. Details are in
the Supplementary Materials and Methods.
2.11. Statistical analysis
All statistical calculations were carried out using SPSS statistical
software (version 17.0, SPSS Inc., Chicago, IL). P values < 0.05 were
considered signiﬁcant, and all tests were two-sided. Kaplan–Meier
curves were used to estimate DFS.
3. Results
3.1. Downregulation of miR-30a is a frequent event in HCC tissues and
associated with worse prognosis
In a preliminary experiment, we observed that miR-30 family
members (miR-30a/b/c/d/e), especially miR-30a, were signiﬁcantly
Fig. 3. MiR-30a inhibits migration, invasion and metastasis of MHCC97H and Hep3B cells. After transfection of MHCC97H and Hep3B cells with (A) miR-30a mimics or (B)
inhibitors for 3 days, extracted total RNA was analyzed by qPCR to conﬁrm augmented or attenuated miR-30a expression, respectively. Data are presented as relative
expression (delta-delta Ct compared with RNU6B). (C and D) The migration capacity of MHCC97H and Hep3B cells was assessed by the wound healing assay. (E) Invasive
ability of MHCC97H and Hep3B cells was evaluated by transwell invasive assay. In (C–E), cells without transfection were used as negative controls. Data are presented as
mean ± SEM (n = 3). n.s. indicates not signiﬁcant. ⁄P < 0.05, ⁄⁄P < 0.01.
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(data not shown). Here we further examined miR-30a expression
in 63 paired HCC and para-cancerous tissues using qPCR. Notably,
miR-30a was downregulated in 87% (55/63) of the examined HCC
tissues (Fig. 1A). Next we analyzed the levels of miR-30a in several
HCC cell lines, including HepG2, Huh7, Hep3B, SMMC7721 and
MHCC97H, and the normal human liver cell line LO2. Consistent
with the above results, qPCR analysis revealed a similar decrease
of miR-30a in multiple HCC cell lines compared with LO2 cells
(Fig. 1B).
We next investigated whether miR-30a downregulation was
correlated with clinical features or prognosis of HCC patients. An
association between decreased miR-30a expression and intrahe-
patic metastasis, advanced tumor-node-metastasis (TNM) stageand high Edmonson pathological classiﬁcation was observed
(Supplementary Table 1). Furthermore, lower miR-30a level was
associated with shorter DFS (P = 0.015) as determined by the
Kaplan–Meier method (Fig. 2). To exclude the confounder effect,
we further performed Cox proportional hazards regression analy-
sis. Univariate analysis was ﬁrst conducted to identify factors that
affected DFS, followed by multivariate analysis, which controlled
for potential confounders (Table 1). Strikingly, multivariate analy-
sis further conﬁrmed that reduced miR-30a level is an independent
predictor for shorter DFS of HCC patients (HR = 3.2; P = 0.002)
(Table 1).
We next evaluated the levels of miR-30a in HCC tissues with
or without metastasis. The levels of miR-30a in HCC tissues of
patients with metastasis were approximately 1.1-fold lower than
Fig. 4. MiR-30a prevents EMT in MHCC97H and Hep3B cells. Overexpression of
miR-30a increased E-cadherin protein expression and downregulated vimentin
protein expression signiﬁcantly in both MHCC97H and Hep3B cells. Silencing miR-
30a reduced E-cadherin expression and increased the expression of vimentin in
both MHCC97H and Hep3B cells. Non-transfected cells were used as a negative
control.
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miR-30a expression level was related to metastasis in patients
with HCC. This result indicates that the loss of miR-30a may con-
tribute to metastasis of HCC.
Collectively, these data suggest that deregulation of miR-30a
may contribute to the development of HCC.
3.2. Downregulation of miR-30a promotes cell migration, invasion and
epithelial–mesenchymal transition (EMT) in HCC
The above ﬁndings prompted us to explore the biological signif-
icance of miR-30a in tumorigenesis and progression. It is well
known that a high frequency of intrahepatic and extrahepatic
metastasis in the early stage contributes to poor prognosis of
HCC patients, which is also the critical factor involved in the disap-
pointing survival following curative liver resection [18]. Thus, it is
necessary to establish the factors that act as HCC metastatic mark-
ers. We therefore analyzed the effect of miR-30a on the migration
and invasion of HCC cells.
Quantitation of miR-30a expression after transfection with
miR-30a mimics conﬁrmed miR-30a overexpression (Fig. 3A) and
decreased endogenous miR-30a in HCC cells transfected with
miR-30a inhibitors (Fig. 3B). The wound healing assay and trans-
well invasive assay revealed that increased miR-30a resulted in
signiﬁcantly inhibited migration and invasion in MHCC97H and
Hep3B cells (Fig. 3C–E). Furthermore, transfection of MHCC97H
and Hep3B cells with anti-miR-30a promoted cell migration and
invasion compared with negative controls (Fig. 3C–E). Representa-
tive images of migration and invasion are shown in Supplementary
Fig. 1A and B and Supplementary Fig. 2. Together these results
revealed that downregulation of miR-30a could promote HCC cell
migration and invasion.
During tumor progression, cancer cells can acquire motility and
invasive ability by initiating the EMT process, which can potentially
lead to distant metastases [19]. MiRNAs are emerging as major reg-
ulators of tumorigenesis and have also been linked to the regulation
of EMT in the development of cancer [20,21]. To investigate whether
miR-30a is a crucial regulator of EMT, MHCC-97H and Hep3B cells
were transfected with miR-30a mimics or inhibitors. As shown in
Fig. 4, overexpression of miR-30a in MHCC-97H and Hep3B cells
promoted the expression of E-cadherin and decreased expression
of vimentin, which is associated with reversed EMT. Conversely,
knockdown of miR-30a in MHCC-97H and Hep3B cells by transfec-
tion with miR-30a inhibitors resulted in reduced expression of E-
cadherin and increased expression of vimentin, suggesting that
reduced miR-30a promotes EMT (Fig. 4).
We further analyzed the associations among miR-30a level, E-
cadherin expression and vimentin expression in human HCC tissues.
Samples from 63 HCC cases, in which miR-30a levels had been pre-
viously determined, were immunohistochemically analyzed for E-
cadherin and vimentin expression (Fig. 5A). We conﬁrmed a positive
relationship between the expression of miR-30a and E-cadherin in
HCC tissues, indicating that miR-30a downregulation was signiﬁ-
cantly associated with lower E-cadherin levels (Fig. 5B, Supplemen-
tary Fig. 3A). Furthermore, miR-30a levels were inversely correlated
with vimentin expression (Fig. 5C, Supplementary Fig. 3B).
Taken together, our data conﬁrm that downregulation of miR-
30a may be responsible for the progression of EMT in HCC, which
in turn promotes migration and invasion of HCC cells.
3.3. MiR-30a directly regulates SNAI1 expression
Next we explored the molecular mechanisms responsible for
the functions of miR-30a observed above. Predicted target genes
of miR-30a were retrieved and analyzed using publicly available
databases (TargetScan and Miranda). The SNAI1 transcription fac-tor, which is known to be relevant to EMT and tumor metastasis,
was predicted as one of the targets of miR-30a (Fig. 6A). This pre-
diction was validated using dual-luciferase reporter gene assays in
HEK293T cells. Cotransfection of miR-30a signiﬁcantly suppressed
the activity of a luciferase reporter containing the wild-type 30-UTR
of SNAI1 but not that of the mutant reporter (Fig. 6B). In addition,
inhibition of endogenous miR-30a by anti-miR-30 led to increased
luciferase activity of the wild-type reporter but not the mutant
reporter (Fig. 6C). These results were reproducible in MHCC97H
cells (Supplementary Fig. 4A and B).
Further investigation showed that cells transfected with miR-
30a showed reduced expression of endogenous SNAI1 protein
and mRNA (Fig. 6D). In addition, antagonism of endogenous miR-
30a resulted in the upregulation of SNAI1 protein and mRNA
(Fig. 6D). The correlation between miR-30a levels and SNAI1 levels
was further examined in HCC tissues. SNAI1 was analyzed by
immunohistochemistry and miR-30a levels were evaluated by
qPCR in the same set of specimens shown in Fig. 1A. Notably,
miR-30a level was inversely correlated with SNAI1 expression
(Fig. 6E and F, Supplementary Fig. 5).
Together, these data suggest that miR-30a may negatively reg-
ulate the expression of SNAI1 by directly targeting its 30-UTR.
3.4. SNAI1 is involved in the effects of reduced miR-30a on promoting
cell migration, invasion and EMT changes
To evaluate whether SNAI1 is involved in the effects of reduced
miR-30a on increased migration and invasion, MHCC97H cells
were transfected with plasmids expressing SNAI1, which resulted
in greatly increased SNAI1 protein levels (Fig. 7A). Ectopic expres-
sion of SNAI1 abrogated the inhibitory effect of miR-30a on migra-
tion and invasion, and further enhanced the effect of anti-miR-30a
on promoting migration and invasion in MHCC97H cells (Fig. 7B
and C). Representative images of migration and invasion are shown
in Supplementary Fig. 6A and B.
We next investigated whether overexpression of SNAI1 could
counteract the inhibitory function of miR-30a on EMT. Plasmids
encoding SNAI1 were cotransfected with miR-30a or anti-miR-
30a into MHCC97H cells, and the expression of SNAI1, E-cadherin
and vimentin was analyzed by Western blot. Notably, overexpres-
sion of SNAI1 abrogated the effect of miR-30a on changes in pro-
tein markers associated with EMT, and strengthened the effect of
anti-miR-30a on EMT changes in MHCC97H cells (Fig. 7A). These
observations suggest that SNAI1 is potentially involved in the
miR-30a-regulated EMT process. Taken together, our data suggest
that downregulation of miR-30a may stimulate migration and
invasion by promoting the expression of SNAI1, and in turn, facil-
itating the EMT process.
Fig. 5. MiR-30a levels positively correlated with E-cadherin expression and inversely correlated with vimentin expression in human HCC tissues. (A) Representative images of
immunohistochemical staining for E-cadherin and vimentin. Magniﬁcation, 400. Scale bar = 50 lm. (B) HCC tumors with lower miR-30a level displayed lower E-cadherin
expression. (C) HCC tumors with lower miR-30a level showed higher Vimentin expression. Low-miR-30a (n = 32) and high-miR-30a expressing tumors (n = 31) were
distinguished as described in Fig. 2. Expression of E-cadherin and vimentin was quantiﬁed in immunohistochemical staining using an IOD by Image-Pro Plus 6.0 software. For
(B and C), the Mann Whitney test was performed. The central horizontal line indicates the mean value and the error bar indicates SEM. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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Although altered miRNA expression has been found in various
types of malignancies [22–24], the molecular mechanisms by
which miRNAs modulate the behavior of cancer cells are stilllargely unknown. Here we demonstrated that downregulation of
miR-30a was a frequent event in HCC tissues and could serve as
an independent prognosis predictor for HCC patients. Furthermore,
downregulation of miR-30a contributed to cancer cell migration
and invasion, which was associated with EMT. Our ﬁndings also
Fig. 6. SNAI1 is a direct target of miR-30a. (A) SNAI1 is predicted as a target of miR-30a. (B) Luciferase assays of cells cotransfected with miR-30a mimic or miR-NC (negative
control), pRL-TK and ﬁreﬂy luciferase reporter plasmid containing the wild-type or mutant 30-UTR of SNAI1. (C) Luciferase assays of cells transfected with anti-miR-30a or
anti-miR-NC, pRL-TK and the ﬁreﬂy luciferase reporter comprising the wild-type or mutant 30-UTR of SNAI1. pRL-TK expressing Renilla luciferase was cotransfected as an
internal control, and the ﬁreﬂy luciferase activity of each sample was normalized to the Renilla luciferase activity. The normalized luciferase activity of miR-NC or anti-miR-NC
transfectants was set as relative luciferase activity 1, therefore no error bar was shown for miR-NC and anti-miR-NC transfectants. ⁄P < 0.05, ⁄⁄P < 0.01, compared with miR-NC
or anti-miR-NC transfectants. (D) Effects of miR-30a overexpression or suppression on endogenous SNAI1 levels. Forty-eight hours after transfection as indicated, MHCC97H
and Hep3B cells were harvested and analyzed by Western blot and qRT-PCR. (E) Immunohistochemistry staining of SNAI1 in HCC tissues. Representative
immunohistochemical staining in HCC tissues with low miR-30a and high miR-30a expression are shown. Scale bar = 50 lm. (F) Inverse correlation between miR-30a
and SNAI1 levels in HCC tissues. Expression of SNAI1 analyzed by immunohistochemical staining was quantiﬁed using an IOD by Image-Pro plus software (Version, 6.0).
Mature miR-30a levels were examined by qPCR analysis and normalized to RNU6B expression. Statistical analysis was performed using Pearson’s correlation coefﬁcient.
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prevent EMT and inhibited cell migration and invasion. In addi-
tion, we further identiﬁed SNAI1 as a functional target of miR-
30a and demonstrated an involvement of SNAI1 in the effects of
reduced miR-30a on promoting cell migration, invasion and EMT
changes. Our data suggest a fundamental role for miR-30a in
EMT as well as migration and invasion of HCC cells, and implicate
the potential application of miR-30a in prognosis prediction and
cancer therapy.To clarify the clinical prognostic signiﬁcance of miR-30a, we
examined the expression of miR-30a in 63 HCC samples to exam-
ine potential links between the miR-30a expression and survival
prognosis, as well as cancer metastasis. Kaplan–Meier survival
analysis showed that the level of miR-30a was correlated with
DFS, with HCC cases expressing lower levels of miR-30a exhibiting
shorter DFS. Downregulation of miR-30a was previously been
reported to be a poor prognostic marker in multiple types of cancer
[9,11], which is consistent with our results. Our conclusions indi-
Fig. 7. MiR-30a exerts its function by suppressing SNAI1. (A) Ectopic expression of SNAI1 abrogates the effect of miR-30a on changes in protein markers associated with EMT,
and further enhances the effect of anti-miR-30a on EMT changes in MHCC97H cells. After cotransfection of MHCC97H cells with the indicated RNA duplex for 3 days, protein
markers associated with EMT were analyzed by Western blot. b-Actin was used as an internal control. (B and C) Upregulation of SNAI1 abrogates the inhibiting effect of miR-
30a on migration and invasion, and strengthens the promoting effect of anti-miR-30a on migration and invasion. Three days after cotransfection with the indicated RNA
duplex, the migration and invasion ability of MHCC97H cells were evaluated by wound healing assay and transwell invasive assay, respectively. Non-transfected cells were
used as a negative control. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, comparison between two groups as indicated.
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outcome in HCC. Prospective clinical studies are necessary to con-
ﬁrm whether miR-30a is a reliable clinical predictor of prognosis
for cancer patients.
Migration, invasion and metastasis are major cellular processes
that must be circumvented to prevent malignant tumor progres-
sion. Downregulation of miR-30a may enhance the migration,
invasion and metastases of cancer cells, and in turn, stimulate
the development of tumors. EMT is a key step that facilitates tumor
migration and invasion. Increasing evidence has supported an
important role for miRNAs in regulating EMT [25,26], which
encouraged us to study the role of novel miRNAs in the regulation
of EMT. In this study, we employed MHCC97H and Hep3B cells to
examine how miR-30a exerts its function and modulates the
migration and invasion of cancer cells, and our results provide
new evidence for roles of miR-30a in cancer cell migration and
invasion. Our ﬁndings show that ectopic expression of miR-30a
in HCC cells could prevent EMT and inhibit cell migration and inva-
sion, and downregulation of miR-30a can facilitate EMT change
and promote migration and invasion in HCC cells. These results
indicate that miR-30a has important roles in regulating EMT. Fur-
thermore, our data in 63 paired HCC tissues showed that the
expression of miR-30a was lower in patients with metastasis than
patients without metastasis, revealing a clear correlation between
miR-30a expression and HCC metastasis. Together with the in vitro
ﬁndings showing that reduced miR-30a in HCC cell lines promotes
migration and invasion, these results further conﬁrmed the roles of
miR-30a in migration, invasion and metastasis of HCC cells.
To completely understand the speciﬁc biological functions of
miR-30a, identiﬁcation of targets of miR-30a is critical. We used
the miRNA target prediction program and a dual-luciferase report
assay to demonstrate that miR-30a directly down regulates SNAI1
by binding its 30-UTR. Furthermore, ectopic expression of miR-30aresulted in downregulated expression of endogenous SNAI1 pro-
tein and mRNA, while targeted knockdown of miR-30a increased
the expression of SNAI1 protein and mRNA. In addition, we
observed signiﬁcant inverse correlations in clinical samples
between miR-30a and SNAI1 expression levels in patient tumors,
which supports the regulation of miR-30a on SNAI1 observed
in vitro. Together these results indicate that SNAI1 is a direct phys-
iological target of miR-30a.
SNAI1 is a well-known transcriptional repressor of E-cadherin
that binds to three E-boxes in the human E-cadherin promoter
[27]. The adhesion protein E-cadherin plays a central part in the
process of epithelial morphogenesis, and loss of E-cadherin expres-
sion is a key event in EMT. Consistent with this, ectopic expression
of miR-30a repressed EMT, accompanied by increased levels of E-
cadherin. Furthermore, in the rescue experiment, overexpression
of SNAI1 abrogated the inhibitory effect of miR-30a on EMT and
strengthened the effect of anti-miR-30a on promoting EMT in
MHCC97H cells. This study provides a new link between miR-30a
and SNAI1 in the regulation of HCC cell EMT programs. EMT is a
crucial step in tumor invasion and metastasis, therefore inhibition
of EMT represents a very promising therapeutic strategy to prevent
tumor invasion and metastasis [28]. In this study, we found that
forced expression of miR-30a in HCC cell lines could decrease
migration and invasion abilities. This ﬁnding might provide a valu-
able tool in the development of new therapeutic avenues against
invasive and metastasis.
In the current study, we investigated the potential role of miR-
30a in tumor progression and its underlying mechanisms. Our
results suggest that downregulation of miR-30amay play an essen-
tial role in the development of HCC, and that miR-30a may be
employed as a prognosis marker and therapeutic target for HCC.
Nevertheless, these data should be further validated in indepen-
dent cohorts and prospective trials.
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